

Corrigendum: Large-scale chemical dissection of mitochondrial function

Bridget K Wagner, Toshimori Kitami, Tamara J Gilbert, David Peck, Arvind Ramanathan, Stuart L Schreiber, Todd R Golub & Vamsi K Mootha
Nat. Biotechnol. 26, 343–351 (2008); published online 24 February 2008; corrected after print 8 July 2008

In the version of this article initially published, on p.348, column 2, paragraph 2, line 7, the following sentence was incorrect: “Statins block the synthesis of cholesterol—a precursor to ubiquinone....” It should have read “Statins block the synthesis of mevalonate, a precursor not only of cholesterol but also ubiquinone,” The error has been corrected in the HTML and PDF versions of the article.

Corrigendum: Isolation and directed differentiation of neural crest stem cells derived from human embryonic stem cells

Gabsang Lee, Hyesoo Kim, Yechiel Elkabetz, George Al Shamy, Georgia Panagiotakos, Tiziano Barberi, Viviane Tabar & Lorenz Studer
Nat. Biotechnol. 25, 1468–1475 (2007); published online 25 November 2007; corrected after print 8 July 2008

In the version of this article initially published, a reference was missing from the first paragraph. A new sentence and the reference (no. 6) have been added: “A recent study characterized neural crest differentiation from cloned bovine blastocysts via a neural rosette intermediate⁶. Other....” Subsequent references have been renumbered. The corrections have been made in the HTML and PDF versions of the article.

Erratum: Looking forward, looking back

Anonymous

Nat. Biotechnol. 26, 475 (2008); published online May 2008; corrected after print 13 June 2008

In the version of this article initially published, in paragraph 4, the generic name and ligand given for Avastin are incorrect. The correct generic name is bevacizumab and its target is VEGF (vascular endothelial growth factor). The error has been corrected in the HTML and PDF versions of the article.

Erratum: Is personalized medicine finally arriving?

Malorye Allison

Nat. Biotechnol. 26, 509–517 (2008); published May, 2008; corrected after print 8 July 2008

In the version of this article initially published, Table 1 (pp. 510–511) contained two errors. In the entry for Agendia, the product MammaPrint was described as providing information on chemotherapy options for breast cancer patients. In fact MammaPrint is a prognostic test. In the entry for Genomic Health, the product Oncotype Dx was described as providing information on breast cancer recurrence. Oncotype DX also provides information on the response to chemotherapy. The error has been corrected in the HTML and PDF versions of the article.